Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)

The National Institutes of Health (NIH) is accepting applications for the grant program "Schizophrenia and Related Disorders during Mid- to Late-Life" (R01 Clinical Trial Optional). This initiative aims to support translational research to understand the emergence and progression of schizophrenia and related disorders in individuals aged 35 and older. The program seeks to identify mechanisms underlying these conditions and potential targets for prevention and treatment efforts. Eligible applicants include state and local governments, higher education institutions, tribal entities, nonprofits, small businesses, for-profit organizations, and other eligible entities. Applications can propose studies that do or do not involve clinical trials. There is no cost-sharing or matching requirement. The next application deadline is November 18, 2024, with subsequent cycles continuing until September 7, 2026. Proposals should focus on advancing knowledge of schizophrenia and related disorders in mid- to late-life stages, emphasizing innovative approaches to improve understanding and inform future therapeutic development.